发明名称 |
Liquid formulation comprising clozapine, quetiapine, a salt of quetiapine and/or olanzapine for oral administration |
摘要 |
<p>Use of composition comprising clozapine (20-100 mg/ml), quetiapine (25-100 mg/ml), one or more hardly soluble acid addition salt of quetiapine (quetiapine base) (25-100 mg/ml) and/or olanzapine (1-10 mg/ml); benzyl alcohol and/or phenylethyl alcohol (0-20 mg/ml); propylene glycol (25-150 mg/ml) and up to 50 mg/ml of ethanol and/or up to 0.5 wt.% of one or more 3-4C-alkanol; one or more ethereal oil (0-50 mg/ml), flavor and/or sweetener; and one or more liquid polyethylene glycol (residue up to 1 ml), to prepare a solution for oral administration, is claimed. ACTIVITY : Neuroleptic. MECHANISM OF ACTION : None given.</p> |
申请公布号 |
EP1880725(A1) |
申请公布日期 |
2008.01.23 |
申请号 |
EP20070012448 |
申请日期 |
2007.06.21 |
申请人 |
NEURAXPHARM ARZNEIMITTEL GMBH U. CO. KG |
发明人 |
SEWARTE-ROSS, GUENTER, DR. |
分类号 |
A61K31/5513;A61K9/08;A61K31/554;A61K47/10;A61P25/18 |
主分类号 |
A61K31/5513 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|